Overview

Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of deferasirox in patients with cardiac MRI T2* < 20 msec.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Deferasirox